Founded in 2014, Lovinium Group Limited (LVGL) has gained vast experience, advanced technology, and a knowledgeable team from around the globe, which has helped us establish ourselves as a reputable company in Research Laboratories in the fields of Biotechnology and the Cosmetic Industry. The LVGL team in Production, R&D, and Quality Assurance regularly reviews and suggests scope for improvement of the Regenerative treatment plans for our clients. With continuous effort and its advanced technology, LVGL is making great strides to become one of the world’s leading companies investing in biotechnology, human and animal regenerative medicine, induced pluripotent stem cells (iPSCs), healthcare equipment, and cultured or clean meat.
With years of experience, we are making a step forward and committed to delivering the best treatment for our valued clients through our primary focus on Growth Hormone and Pituitary. We ensure that our products are tested rigorously on various animals, with a high level of quality checks and technical specifications to ensure their safety and efficacy.
LVGL is dedicated to providing the highest quality services and customer satisfaction. We offer you a diverse range of specialized treatment facilities and are determined to improve productivity and continuously focus on innovation and upgrading our analytical instruments. We are proud to be able to bring you the value of life and leading-edge technology.
Mission & Vision
We are committed to saving lives and preventing and curing diseases by engaging in regenerative medicine research. We want to improve the quality of life, cure diseases, and make grieving families whole again. To provide a scientific platform for creating, perfecting, and commercializing regenerative medicine therapies, we offer novel reagents and tools that enable scientists to design better drugs faster and more efficiently.
Lovinium Group is a global regenerative medicine company focusing on developing and commercializing therapies to cure, repair, and replace organs damaged by disease. Our vision is to eliminate the organ shortage crisis, which kills thousands each year, and to significantly expand the number of patients that can benefit from transplantation. We work closely with clinicians, patients, and families to deliver products that address unmet medical needs in areas of high unmet need. Our development programs are backed by decades of scientific research — undertaken at our research centers or with collaborators worldwide — and our production capabilities are designed to meet regulatory standards for quality control and safety testing.